Text Size

Isoflavones and the Coronary Circulation in Men and Women With Coronary Artery Disease

This study has been completed.
Sponsor:
Information provided by:
Imperial College London
ClinicalTrials.gov Identifier:
NCT00287690
First received: February 6, 2006
Last updated: May 23, 2006
Last verified: February 2006
History of Changes
  Purpose

The aim of this study is to investigate the effect of genistein administration on coronary arteries in humans. We will measure the size of a coronary artery and the speed and amount of blood flow in response after subjects have ingested Supro® drinks (a soy protein drink containing genistein).


Condition Intervention Phase
Coronary Artery Disease
 Drug: genistein (Supro)
 Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: The Effect of Genistein (Supro®) on Coronary Artery Diameter and Blood Flow in Men and Women With Coronary Heart Disease

Resource links provided by NLM:

Drug Information available for: Genistein
U.S. FDA Resources

Further study details as provided by Imperial College London:

Primary Outcome Measures:
  • Coronary artery diameter

Secondary Outcome Measures:
  • Coronary blood flow

Estimated Enrollment: 26
Study Start Date: October 1999
Estimated Study Completion Date: April 2003
  Eligibility

Ages Eligible for Study:   30 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Aged 30-75 years
  • Patients requiring diagnostic coronary angiography
  • Presence of coronary artery disease on angiogram but with at least one non-obstructed (lesions <70% narrowed compared with the adjacent normal part of the vessel) atheromatous vessel (confirmed at diagnostic cardiac catheterisation)
  • Female patients must be postmenopausal (FSH>40 IU/L)
  • Willing to give informed, written consent

Exclusion Criteria:

  • Age <30 or >75 years
  • Allergy to radiographic contrast media
  • Sino-atrial disease or significant bradycardia
  • Concomitant medication with persantin (dipyridamole) or theophyllines
  • Asthma
  • Hypertension
  • Left ventricular hypertrophy or dysfunction (clinical/ECG/echo/CXR)
  • Female patients with FSH<40 IU/L (postmenopausal)
  • Female patients currently taking hormone therapy, or who have taken hormone therapy in previous 6 months
  • Unwilling to give written informed consent
  • Participation in another study within previous 60 days
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00287690

Locations
United Kingdom
Royal Brompton & Harefield NHS Trust
London, United Kingdom, SW3 6NP
Sponsors and Collaborators
Imperial College London
Investigators
Principal Investigator: Peter Collins, MD, FRCP Imperial College London
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00287690     History of Changes
Other Study ID Numbers: 98-170
Study First Received: February 6, 2006
Last Updated: May 23, 2006
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by Imperial College London:
arteries
blood flow
coronary artery disease
diet

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Genistein
Phytoestrogens
Estrogens, Non-Steroidal
Estrogens
 Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Anticarcinogenic Agents
Protective Agents
Antineoplastic Agents
Therapeutic Uses
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on May 23, 2013